


POLYMYXIN B

Quick update on dilution protocol



Targeted Organisms

For multidrug resistant gram negatives (eg. *Acinetobacter baumannii* and *Pseudomonas aeruginosa*)

Formulation: Inj 500,000 unit/vial

Dosage for IV Infusion:


Loading dose: 25,000 units/kg/dose (Max: 2,500,000 units/ 5 vials) infused over 2 hours.

Maintenance dose: 15,000 units/kg/dose every 12 hours over 60 minutes.

(Use **actual body weight**. If patient is **obese**, use **adjusted body weight**)

Administration (central/peripheral line):

MEDICATION DOSING PROTOCOL (UNITS/KG)



ALTERNATIVE SMALLER DILUENT VOLUME

FOR SMALLER VOLUME USE NS (NORMAL SALINE) ONLY

Number of vials	Min volume (25 ml/vial)	Max volume (100 ml/vial)
1	25	100
2	50	200
3	75	300
4	100	400

1. **Loading dose:** 25,000 units/kg (max: 2,500,000 units) dilute in **500 ml NS/D5**

- If patient is 60 kg, then 3 vials in 500 ml NS.
- If patient is 100 kg, then 5 vials in 500 ml NS.

2. **Maintenance dose:** 15,000 units/kg dilute in **250 ml NS/D5**

3. Alternatively for smaller diluent volume: **each 500,000 units vial** can be diluted in **25 ml* - 100 ml NS ONLY**.

(*Monitor line when using 25 ml of diluent volume for each vial, **SEEK CONSULTATION FROM AMS PHARMACIST BEFORE USE**)

Note: NS is preferred for these concentrated volumes because it is less acidic than D5. While both maintain a stable, near-isotonic osmolality, NS provides a more neutral environment for the infusion.

REFERENCES

- POLY-MxB (Polymyxin B for Injection U.S.P.) [Package insert]. National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia.
- Lim, T.-P., Hee, D. K.-H., Lee, W., Teo, J. Q.-M., Cai, Y., Chia, S. Y.-H., Leaw, J. Y.-K., Lee, S. J.-Y., Lee, L. S.-U., & Kwa, A. L. (2016). Physicochemical stability study of Polymyxin B in various infusion solutions for administration to critically ill patients. *Annals of Pharmacotherapy*, 50(9), 790-792.

RESULTS FROM DRUGS & THERAPEUTICS COMMITTEE (JKTU) MEETING 1/2026

Here's the summary of the decisions made by the committee:

Formulary Medications

Date of implementation:

Once the stocks of removed drugs are depleted.

RYALTRIS®

Olapatadine +
Mometasone Nasal
Spray



NEW DRUG ENTRY REQUEST

A*: ENT Specialists only. **Only for step up therapy in allergic rhinitis**
400 patients a year
(1 month/patient/year)

Drug removed: Azelastine Hydrochloride 137mcg & Fluticasone Propionate 50mcg Nasal Spray (DYMISTA)–while stocks last

BEYFORTUS®

Nirsevimab
50 mg/0.5 mL
and 100
mg/1.0 mL in
a single-dose
pre-filled
syringe



NEW DRUG ENTRY REQUEST

A*: Neonatologists only.
Prevention of RSV lower respiratory tract disease in infants
RM 300,000/year

Drug removed: Palivizumab 100mg injection (SYNAGIS)

TRIMBOW®

Beclomethasone
dipropionate/
Formoterol
fumarate
dihydrate/
Glycopyrronium
100/6/12.5 mcg
pMDI



NEW DRUG ENTRY REQUEST

A*: Respiratory Specialists only.
COPD or asthma not adequately treated by inhaled corticosteroid and a long-acting beta2-agonist
30 patients a year

Drug removed: Salbutamol 2mg tablets–still in stock as of 25.6.2026

Posaconazole 100mg modified release tablets

NEW DRUG ENTRY REQUEST

A*: Hematologists only.

1. Prophylaxis for allogeneic hematopoietic stem cell transplantation who are at high risk of developing invasive fungal infections.
2. Prophylaxis for induction chemotherapy for ALL/AML expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections.
3. Treatment for disseminated fungal infection if failed itraconazole / fluconazole or intolerant to Amphotericin B Therapy

- Approved for 6 weeks/patient (estimated 13 patients/year if 4 patients are on the suspension).
- To share budget of RM 120,000 with Posaconazole suspension.
- Posaconazole suspension kept only for patients who cannot swallow tablets



New Medications already in SF Pharmacy

Date of implementation:

Once the stocks of removed drugs are depleted.

Lorlatinib 25mg tablets (LORVIQUA®)

Approval:

A*: Radiotherapists & Oncologists only
(For JPA & staff claim)

Drug removed:

Erlotinib 100mg tablet–stock has depleted.

Indication:

ALK positive advanced non-small cell lung cancer

Lurasidone 40mg & 80mg tablets (LURATA®)

Approval:

A*: Psychiatrists only (For JPA & staff claim)

Drug removed:

Paliperidone XR 6mg & 9mg tablet

Indication:

Bipolar depression, Bipolar mixed, MDD with mixed features, Schizophrenia & Schizoaffective

Ripasudil Hydrochloride Hydrate 0.4% eye drop (GLANATEC®)

Approval:

A*: Ophthalmologists only (For JPA & staff claim)

Drug removed:

Brimonidine tartrate 2mg + Timolol 5mg (COMBIGAN)

Indication:

Reduction of intraocular pressure (adjunctive therapy)

Finerenone 10mg & 20mg tablets (FIRIALTA®)

Approval:

A*: Nephrologists only (For JPA & staff claim)

Drug removed:

Imidapril 5mg & 10mg tablet

Indication:

Treatment of chronic kidney disease associated with type 2 diabetes in adults

Inclisiran 284 mg Injection (SYBRAVA®)

Approval:

A*: Cardiologists only (For JPA & staff claim)

Drug removed:

Rosuvastatin 20mg tablet (CRESTOR), generic
Rosuvastatin is already placed in formulary

Indication:

Primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet

CEKAP, PANTAS, MESRA

ILMU, MUTU DAN BUDI